US 12,109,258 B2
Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections
David Weiner, Merion, PA (US); Emma Reuschel, Philadelphia, PA (US); Bernadette Ferraro, La Jolla, CA (US); and Ahmed S. I. Aly, New Orleans, LA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US); Ahmed S.I. Aly, New Orleans, LA (US); Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US); and The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US)
Appl. No. 16/302,718
Filed by The Trustees of the University of Pennsylvania, Philadelphia, PA (US); Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US); THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, Philadelphia, PA (US); and Ahmed S. I. Aly, New Orleans, LA (US)
PCT Filed May 19, 2017, PCT No. PCT/US2017/033617
§ 371(c)(1), (2) Date Nov. 19, 2018,
PCT Pub. No. WO2017/201454, PCT Pub. Date Nov. 23, 2017.
Claims priority of provisional application 62/338,841, filed on May 19, 2016.
Prior Publication US 2019/0307870 A1, Oct. 10, 2019
Int. Cl. A61K 39/015 (2006.01); A61K 39/00 (2006.01); A61P 33/06 (2006.01); C07K 14/445 (2006.01)
CPC A61K 39/015 (2013.01) [A61P 33/06 (2018.01); C07K 14/445 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55527 (2013.01); A61K 2039/55538 (2013.01); C07K 2319/02 (2013.01); C07K 2319/42 (2013.01); Y02A 50/30 (2018.01)] 12 Claims
 
1. A nucleic acid molecule comprising one or more nucleic acid sequence that encodes one or more consensus Plasmodium spp. liver stage (LS) immunogen selected from the group consisting of EXP1 (export protein 1), EXP2 (export protein 2), EXP23 (export protein 23), ICP (inhibitor of cysteine protease), TMP21 (transmembrane protein 21), UIS3 (upregulated in infective sporozoites-3), UIS10 (upregulated in infective sporozoites-10), SPECT1 (sporozoite microneme protein essential for cell traversal 1), SPECT2 (sporozoite microneme protein essential for cell traversal 2) and RON2 (rhoptry neck protein 2), wherein the nucleic acid sequence is selected from the group consisting of:
a) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO:17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, and SEQ ID NO: 50;
b) a nucleic acid sequence that encodes an amino acid sequence comprising a fragment comprising at least 90% of the full length of the amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 35, SEQ ID NO: 38, and SEQ ID NO: 50;
c) a nucleic acid sequence that encodes the amino acid sequence comprising at least 90% homology to the amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: NO: 35, SEQ ID NO: 38, and SEQ ID NO: 50;
d) the nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 54, and SEQ ID NO: 55;
e) a nucleotide sequence comprising a fragment comprising at least 90% of the full length of the nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 54, and SEQ ID NO: 55; and
f) a nucleotide sequence comprising at least 90% identity to the nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 54, and SEQ ID NO: 55.